Intensive Care Therapy of Covid-19 Disease in Germany

Completed

• Conditions: COVID; ARDS

• Registration Number: NCT04455451
• Lead Sponsor: University Hospital Tuebingen

Brief Summary

Multi-center retrospective and prospective observational study of Covid-19 patients with severe or critical illness treated on a German ICU

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-01
• Study First Submitted QC: 2020-07-01
• Study First Posted: 2020-07-02
• Study Start: 2020-08-06
• Primary Completion: 2021-08-15
• Status Verified: 2021-09
• Study Completion: 2021-09-30
• Last Update Submitted: 2022-01-11
• Last Update Posted: 2022-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2054

Inclusion Criteria

• Age above 18 years
• Covid-19 disease (positive SARS-CoV-2 PCR)

Exclusion Criteria

-none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality	up to 150 days	ICU Mortality of patients

Secondary Outcome Measures

Name	Time	Method
ICU length of stay	up to 150 days	Intensive care unit length of stay

Trial Locations

Locations (27)

RWTH Aachen - Department for operative Intensive Care Medicine and intermediate Care; 🇩🇪 Aachen, Germany

Zollernalbklinikum; 🇩🇪 Balingen, Germany

Charité Universitätsmedizin Berlin; 🇩🇪 Berlin, Germany

UH Bochum - Department for Anesthesiology and Intensive Care Medicine; 🇩🇪 Bochum, Germany

Universitätsklinikum Bonn; 🇩🇪 Bonn, Germany

Universitätsklinikum Carl Gustav Carus Dresden; 🇩🇪 Dresden, Germany

Ev. Krankenhaus Bethesda Duisburg Klinik für Anästhesiologie und Intensivmedizin; 🇩🇪 Duisburg, Germany

Univerrsitätsklinikum Düsseldorf; 🇩🇪 Düsseldorf, Germany

Universitätsklinikum Essen; 🇩🇪 Essen, Germany

Universitätsklinikum Frankfurt; 🇩🇪 Frankfurt, Germany

Scroll for more (17 remaining)